CLINICAL_TRIALS
trial_result
· 2012-04-03
Clinical Trial Update: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) [Phase 2]
Summary
A Phase 2 pharmacokinetics study of epratuzumab in systemic lupus erythematosus has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: TERMINATED